Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids; Christine E. Ryan; Benjamin L. Lampson; Yue Ren; Svitlana Tyekucheva; Stacey M. Fernandes; Jennifer L. Crombie; Austin I. Kim; Matthew Weinstock; Josie Montegaard; Heather A. Walker; Claire Greenman; Victoria Patterson; Caron A. Jacobson; Ann S. LaCasce; Philippe Armand; David C. Fisher; Steve Lo; Adam J. Olszewski; Jon Arnason; Inhye E. Ahn; Jennifer R. Brown

doi:10.1200/jco-24-02503

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

AVO was highly active and well tolerated in patients with previously untreated high-risk CLL, supporting its use as a new standard-of-care treatment option.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davids et al. (2024) studied this question.

synapsesocial.com/papers/69df6e4258b92af24d7a18da https://doi.org/10.1200/jco-24-02503

View Full Paper

Ask AI

Bookmark

Share

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading